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most lethal malignant diseases known to mankind.
Within 5 years of diagnosis the majority of patients will
die.
Despite liberal endoscopy in patients with reflux
symptoms and routine endoscopic surveillance for
Barrett’s esophagus, most patients who have adenocar-
cinoma of the esophagus present de novo with dyspha-
gia and have large tumors. Using endoscopic ultra-
sound, we now have the capability to identify patients
with advanced disease, including those with transmur-
al tumors.2,3 In many centers these patients are target-
ed for neoadjuvant therapy. Before this alternative ther-
apy is widely adopted, it is imperative that the results
of complete surgical resection alone be defined. Since
1981 our group has used en bloc esophagectomy with
systematic mediastinal and abdominal lymphadenecto-
my to treat patients with esophageal adenocarcinoma.
We reviewed our experience with this procedure in
A denocarcinoma is now the most common esopha-geal cancer in the United States. In white men its
incidence has risen 10% per year during the past
decade, and it now ranks in the top 15 cancers affecting
this group.1 Esophageal adenocarcinoma is one of the
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patients with transmural adenocarcinoma of the lower
esophagus and gastroesophageal junction to determine
the prevalence and location of node metastases, the
feasibility of performing an R0 resection, and the out-
come in terms of disease recurrence and survival. 
Methods
The study population consisted of 44 patients who under-
went en bloc esophagectomy for transmural (T3) adenocarci-
noma of the lower esophagus or gastroesophageal junction.
All operations were performed by one group of surgeons and
represent their cumulative experience at three different insti-
tutions between 1981 and 1998. There were 40 men and 4
women, with a median age of 58 years (range 25–73 years).
None of the patients had received preoperative chemotherapy,
radiotherapy, or prior esophageal or gastric resection. All
patients had a barium radiograph of the upper gastrointestinal
tract, upper gastrointestinal endoscopy with endoscopic ultra-
sound when feasible, and computed tomography of the chest
and abdomen.
Operative approach. En bloc esophagogastrectomy with
systematic mediastinal and abdominal lymphadenectomy
was performed as previously described.4,5 In brief, the esoph-
agus, azygos vein, and surrounding mediastinal tissues were
removed in continuity. The thoracic dissection extended
superiorly to the carina, laterally to include the left and right
mediastinal pleura, anteriorly to the membranous trachea and
pericardium, posteriorly to the spine and aorta, and inferiorly
to the diaphragm. The abdominal dissection included
removal of the proximal two thirds of the stomach, the greater
omentum, spleen, left gastric and splenic arteries along with
Fig 1. Boundaries of our standard en bloc resection.
Fig 2. Lymph nodes routinely removed with thoracic and
abdominal lymphadenectomy. Location code: 1 = lower para-
tracheal; 2 = subcarinal; 3 = paraesophageal; 4 = parahiatal;
5 = splenic hilum; 6 = splenic artery; 7 = greater curve; 8 =
lesser curve; 9 = left gastric; 10 = hepatic; 12 = portal; 13 =
right gastric; 14 = retropancreatic.
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their surrounding fibro-areolar tissue, and nodal tissue along
the portal vein, common hepatic artery, and celiac axis (Fig
1). Overall, this dissection allowed a reproducible, systemat-
ic removal of all lymph nodes in the following locations: low
paratracheal, subcarinal, paraesophageal, parahiatal, porta
hepatis, hepatic artery, celiac axis, and the retroperitoneal
area of the upper part of the abdomen (Fig 2). In most
patients, gastrointestinal continuity was established by an
isoperistaltic colon interposition.
Analysis of the resected specimens. For this study, two
experienced pathologists re-examined slides from the resect-
ed specimens to identify the depth of invasion of the primary
tumor and to search for areas of intestinal metaplasia
(Barrett’s mucosa) adjacent to the tumor. The location of the
primary tumor was determined by review of the original
pathology report. After the resection the pathologists meticu-
lously searched the specimen for lymph nodes and recorded
their locations. We defined local nodes as those in close prox-
imity to the primary tumor and included the parahiatal, less-
er curve, left gastric artery, and paraesophageal node groups.
Nodes outside these areas, but within the field of the en bloc
resection, were considered distant. Node status was also ana-
lyzed according to the staging system proposed by Korst and
associates.6
Follow-up. Patients were followed up by the operating sur-
geon at 3-month intervals for the first 3 years, twice a year for
the next 2 years, and yearly thereafter. Median follow-up was
23 months (range 4-118 months). Each follow-up visit
included serum and liver chemistry panels, carcinoembryon-
ic antigen level, and computed tomographic scans of the
chest and abdomen. All surviving patients were either seen in
person or contacted by telephone within 3 months of the
preparation of this manuscript. Recurrent tumor located with-
in the field of the original en bloc resection was considered
local recurrence. All patients were included in the survival
analysis, including those dying in the perioperative period
and those dying of causes other than cancer.
Statistical analysis. The c 2 and Fisher exact tests were
used to compare proportions. Survival probabilities were cal-
culated by the method of Kaplan and Meier, and survival
curves were compared by the log-rank method.
Results
All tumors invaded through the esophageal wall but
not into adjacent organs. The primary tumor was locat-
ed in the distal third of the esophagus in 8 patients
(18%) and at the gastroesophageal junction in 36
Fig 3. The frequency of nodal metastases by node location for patients with transmural adenocarcinoma located
at the gastroesophageal junction and distal esophagus who underwent en bloc esophagectomy.
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Fig 4. Actuarial survival for patients with transmural esophageal adenocarcinoma stratified by the number of
lymph node metastases.
Fig 5. Actuarial survival for patients with transmural esophageal adenocarcinoma stratified by the ratio of
involved to total number of removed lymph nodes.
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(82%). Histologic evidence of intestinal metaplasia
was found adjacent to the tumor in 27 patients (61%).
A total of 2340 lymph nodes were excised and
examined histologically. The median number of
lymph nodes removed per patient after systematic
mediastinal and abdominal lymphadenectomy was 51
(range 18-92). Lymph nodes metastases were identi-
fied in 37 of the 44 patients (84%). Despite transmur-
al invasion, 7 patients (16%) had no lymph node
metastases. Of the 37 patients with lymph node
metastases, 16 (43%) had 4 or fewer involved nodes,
and in these patients the majority (69%) had only
local node involvement. In contrast, the majority
(62%) of patients with more than 4 involved lymph
nodes were found to have distant node metastases.
Thus there was a trend toward an increased likelihood
of distant node metastases with increasing number of
involved lymph nodes ( c 2, P = .13). The prevalence of
metastatic nodes in patients with tumors located at the
gastroesophageal junction or in the distal esophagus
is shown in Fig 3. We found that the frequency and
distribution of nodal metastases was similar for both
primary tumor locations.
Twenty-seven patients (61%) had recurrent disease.
The median time to detection of recurrence was 15
months (range 4-32 months). In 26 patients recurrent
disease was manifested by systemic metastases. One
patient had isolated nodal metastases outside the field
of the en bloc dissection. This patient had N0 disease at
resection, and paratracheal nodal recurrence subse-
quently developed 2 years later. The involved paratra-
cheal nodes were resected, and the patient is now dis-
ease-free 5 years after the initial resection. No patient
in this series had anastomotic recurrence. Only 1
patient had recurrent disease in nodes within the field
of the en bloc resection; however, this patient also had
systemic metastases. The likelihood of recurrent dis-
ease after en bloc esophagectomy, whether systemic or
nodal, correlated with the presence and number of
lymph node metastases in the operative specimen, but
not with location of nodes in relation to the primary
tumor (Table I). Median survival after detection of
recurrent disease was 7 months.
Actuarial survival for the entire group of 44 patients
was 26% at 5 years. Three patients died in the periop-
erative period (6.8%). The presence and number of
lymph node metastases were the most significant pre-
dictors of 5-year survival (Fig 4). The ratio of involved
to total removed lymph nodes in each patient also pre-
dicted 5-year survival. Patients with a node ratio of less
than 0.1 had a significantly better survival than those
with a ratio of more than 0.1 (Fig 5). Patients with a
node ratio of more than 0.25 had a particularly poor
prognosis, with a median survival of 7 months (95%
confidence interval: 0–19) and no survival at 5 years.
As shown in Table II, the presence of distant node
metastases as defined either in this study or in the study
by Korst and associates6 was not a statistically signifi-
cant predictor of survival.
Discussion
As one might expect, we found that the majority of
patients with transmural adenocarcinoma of the esoph-
agus have lymph node metastases. Surprisingly, 16% of
these select patients had no involved lymph nodes and
had an 85% 5-year survival. Furthermore, as evidenced
by the near absence of anastomotic and in-field recur-
rence, an R0 resection was accomplished despite the
presence of a transmural esophageal adenocarcinoma
in all patients. We found that 5-year survival was 23%
in patients with 4 or fewer involved nodes, but
decreased to 12% in those with more than 4 lymph
node metastases. Correspondingly, the likelihood of
recurrent disease increased from 53% to 90%, respec-
tively. Patients with more than 10 involved lymph
nodes had a particularly poor prognosis, and all have
recurrent disease or have died of their cancer.
A problem with using the absolute number of
involved lymph nodes after resection to predict the
likelihood of long-term survival is the lack of a mea-
sure for the completeness of the lymphadenectomy.
Recently, the ratio of involved to total number of nodes
removed has been proposed as a more quantitative
method to assess the adequacy of a lymphadenectomy.
Holscher and colleagues7 reported that a ratio of
involved to total removed nodes of 0.3 was the most
effective prognostic parameter to stratify patients into
those likely to die of their disease (>0.3) versus those
likely to have better survival. Our data suggest that a
ratio of 0.1 is a better predictor. A likely explanation for
this apparent discrepancy is that the median number of
removed nodes in our series was 51, compared with 26
in the series by Holscher and coworkers.7 A more
extensive lymphadenectomy results in a greater num-
ber of uninvolved nodes removed, thereby driving
down the node ratio. This emphasizes that the critical
number is not the ratio itself, but instead the total num-
ber of involved and removed nodes. Consequently, a
systematic lymphadenectomy is fundamental in allow-
ing an accurate assessment of the patient’s lymphatic
tumor burden and in determining the likelihood of
long-term survival. The importance of a complete, sys-
tematic thoracic and abdominal lymphadenectomy has
been confirmed in our own experience after transhiatal
resection in patients with a transmural esophageal ade-
nocarcinoma who are elderly or have poor cardiopul-
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monary physiology. In these patients, despite a com-
plete abdominal lymphadenectomy, the node ratio was
unable to predict the likelihood of survival.
We found that adenocarcinomas of the gastro-
esophageal junction and lower esophagus tend to metas-
tasize to similar lymph node regions and that distant or
celiac nodal involvement occurred with primary tumors
in either location and did not preclude long-term sur-
vival. We did note that patients with distant node
metastases tended to have more involved nodes and, as
a consequence, were more likely to have a recurrence
and die of their disease. However, in the absence of a
greater number of involved nodes, distant nodal metas-
tases per se were not predictive of the likelihood of sur-
vival and should not deter resection.
Comparing outcomes between various reports in the
literature is difficult because of the confusion in staging.
However, the 26% 5-year survival in our series com-
pares favorably with the 25% to 33% 5-year survival
reported by others for esophagectomy with limited lym-
phadenectomy.8,9 The survival in our series is particu-
larly noteworthy in that it involved exclusively patients
with transmural disease, whereas the other series
included a variety of stages. Altorki and colleagues10
have recently reported favorable results similar to ours,
with a 34.5% 4-year survival after en bloc resection in
patients with advanced (stage III) esophageal cancer.
They concluded, and we would agree, that en bloc
resection improves survival compared with lesser resec-
tions.10 In our center, during the same period as this
study, we performed 40 transhiatal resections in patients
with transmural adenocarcinoma because of advanced
Table I. Relationship of the presence, number, and location of lymph node metastases to the likelihood of recur-
rence and median survival in patients with transmural esophageal adenocarcinoma who underwent en bloc
esophagectomy (recurrence analysis excluded the 3 postoperative deaths)
No. of involved nodes Node location
0 1-4 >4 Local Distant
Recurrence 1/6 (17%) 8/15* (53%) 18/20* (90%) 14/18† (78%) 12/17† (71%)
Median survival NA 33 (28-37) 17 (16–19) 27 (20-34) 20 (5-34)
(mo) (95% CI)
NA, Not applicable; CI, confidence interval.
*P = .02 ( c 2). 
†P = .7 ( c 2).
Table II. Median and 5-year survivals based on the presence and absence of distant node metastases
Actuarial survival at 5 years Median survival (mo)
Local Distant Local Distant
Local and distant 14 (0–29) 20* (0–40) 27 (20–34) 20 (5–34)
as defined in this study 
(95% CI) 
Korst local and distant 13 (0–34) 8† (0–44) 30 (19–40) 17 (12–23)
(95% CI)
CI, Confidence interval.
*P = .1 (log-rank test: local versus distant).
†P = .2 (log-rank test: local versus distant).
Table III. Summary of multimodality therapy randomized trials for esophageal adenocarcinoma
Three-year Median Local 
First author Arm No. survival (%) survival (mo) recurrence (%)
Walsh12 Surgery 55 6 11 NA
Multimodality 58 32 16 NA
Urba11* Surgery 50 15 18 39
Multimodality 50 32 17 19
NA, Not applicable.
*Data published in abstract form only.
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age or compromised physiologic condition. In this
group survival at 5 years was 7%, and recurrent local
disease developed in 15% of the patients.
Of importance, survival after an en bloc resection for
transmural esophageal adenocarcinoma in this series
compares favorably with published results for various
stages of resectable esophageal cancer treated with
neoadjuvant therapy followed by surgery. The two
most widely quoted randomized trials both report a 3-
year survival of 32% in the neoadjuvant group, with the
best survival occurring in the 20% with complete
pathologic response (Table III).11,12 Three-year sur-
vival for the group of patients with transmural tumors
treated only by en bloc resection in this series was
36%. Given our results with en bloc surgical resection
alone, one must question the utility of routine neoadju-
vant therapy. However, we found that the subgroup of
patients with a transmural tumor and more than 4
lymph node metastases had a 90% likelihood of devel-
oping systemic disease after resection alone. In our
opinion, these patients should be targeted for neoadju-
vant therapy. Furthermore, despite the lack of improve-
ment in survival reported with previous trials, consid-
eration should be given to early adjuvant postoperative
chemotherapy in those patients found on pathologic
review of the specimen to be at high risk for recurrence.
Perhaps aggressive chemotherapy directed at a group
of patients known to have a 90% likelihood of recur-
rence would demonstrate an improvement in survival.
A striking benefit of en bloc resection in patients
with advanced disease was the excellent local control
produced by this operation. Only 1 of the 44 patients in
this study had recurrent disease develop within the field
of the en bloc resection, giving a local failure rate of
2% in this homogeneous population of transmural
tumors. Similarly, Altorki, Girardi, and Skinner10
reported recurrent local disease in 5.4% of patients
after en bloc resection for stage III esophageal cancer.
In contrast, Urba and colleagues11 noted that local fail-
ure occurred in 39% of patients who had transhiatal
esophagectomy alone and in 19% of patients after mul-
timodality therapy that included the same type of resec-
tion. It is interesting to speculate whether, with better
surgical therapy in these trials, the difference in out-
come would vanish, or perhaps even be in favor of
complete surgical resection alone.
Conclusions
We found that the presence and number of lymph
node metastases and the ratio of involved to total
removed nodes are important predictors of recurrent
disease and the likelihood of long-term survival in
patients with transmural adenocarcinoma of the esoph-
agus. In our opinion, an en bloc esophagectomy with
systematic thoracic and abdominal lymphadenectomy
is required to reliably obtain an R0 resection, to achieve
excellent local control, to adequately assess lymphatic
tumor burden, and to predict the likelihood of recur-
rence and cancer-related death.
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Discussion
Dr Alex G. Little (Las Vegas, Nev). Adenocarcinoma of
the gastroesophageal junction is becoming more prevalent
and therefore is of increasing importance. This paper adds
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useful data to the data pool from which decisions and recom-
mendations will be made about two unsettled and important
issues. One is the surgical approach—transthoracic, transhi-
atal, extended en bloc, two-field, three-field, four-field—and
therapy, so your group has performed a valuable service in
providing this information. However, I am not fully persuad-
ed. Clearly the only way these issues are going to be settled
is by prospective randomized comparisons. Despite the
enthusiasm that one surgical group may develop for its way
of doing things, whether it be the operative technique or the
use or nonuse of adjuvant therapy, continuing to simply pre-
sent an experience is no longer going to be sufficient to per-
suade thoracic surgeons or thoracic oncologists.
I have a few questions that reflect my skepticism about the
validity of this study to really prove its point about the role of
en bloc esophagectomy.
First, I noticed that you had accrued 44 patients over 17
years, but the median follow-up was under 2 years, which
suggests that you are comparing patients accrued very recent-
ly with patients distributed over a significant amount of ear-
lier time. I think everyone believes that the biologic behavior
of adenocarcinoma has changed. Does that disturb you at all
or do you think this is a homogeneous patient population?
Dr Nigro. Undoubtedly the epidemiology of esophageal
cancer has changed over the past 20 years and patients are
now referred for treatment with earlier disease. This may be
partially due to our more substantial understanding of those
groups at risk and the recognition of the relationship between
gastroesophageal reflux disease and esophageal adenocarci-
noma. But there is no evidence that the biologic behavior of
esophageal adenocarcinoma has changed. Since all of these
patients had transmural disease, they should be relatively
comparable.
Dr Little. It would seem so, but I am concerned. I do not
think that adenocarcinoma of the gastroesophageal junction
is behaving now the way it did 17 years ago, so that is at least
a concern.
The second question has to do with the fact that even
though all patients have transmural primary tumors, a sur-
prisingly high number had no nodes involved, which actually
makes them have somewhat early disease, certainly stage II.
Since your paper does not address the symptoms in this
patient group, were some of these patients actually identified
in surveillance approaches, rather than being taken care of
because of symptoms?
Dr Nigro. All of the patients in this study presented with
transmural tumors and had symptoms of dysphagia and
weight loss; none of these patients were discovered during
Barrett’s surveillance. In our experience those cancers found
during surveillance tend to have mucosal or submucosal inva-
sion only, and we now consider these (tumors) to represent
early disease.
Dr Little. My final comment and question have to do with
the crux of interpretation of these data. My conclusion contin-
ues to be that survival is more a function of the biologic
behavior and the stage at which the disease is detected rather
than the operative technique, as much as I would like to
believe the latter. For example, survival was excellent in
patients with N0 disease, as one would expect. I understand
the theory that you may detect some micrometastatic deposits
in lymph nodes. Nonetheless, in patients with N0 disease,
extended dissection does not seem to be very beneficial. My
other observation is that patients who had 5 or more lymph
nodes involved did very badly and their 5-year actuarial sur-
vival was just over 10%. I would argue that those patients did
not benefit significantly from an extended resection. 
Finally, the survival in the patients with 1 to 4 involved nodes
was 23%, which is certainly good, but not obviously or dra-
matically better than what has been reported with the so-called
standard techniques. If you follow the argument that in that
case there is no benefit to going beyond what you call local
nodes, the hiatal, left gastric artery, lesser curve, and
periesophageal nodes, which I think most surgeons would rou-
tinely resect, then there is no benefit to going beyond that. That
allows you to keep the greater curvature and use the stomach
for reconstruction, which is a much less complicated and a
much less morbid operation than routinely using the colon.
Do you really believe you have established the role for rou-
tine radical en bloc esophagogastrectomy with removal of
two thirds of the stomach in all patients with adenocarcinoma
of the gastroesophageal junction?
Dr Nigro. We believe that this operation provides for good
survival, excellent local disease control, and accurate stratifi-
cation for subsequent adjuvant therapy. With more limited
resections we have observed a lower survival, a high local
recurrence rate, and inability to accurately stratify patients for
risk of recurrence and cancer-related death.
Dr Gundry. Do you plan to continue this approach or are
you going to investigate some adjuvant therapy or multiple-
modality protocols?
Dr Nigro. One of the main objectives of our work with
esophageal adenocarcinoma has been to establish the rela-
tionship between depth of tumor invasion, node status, and
survival. This information was available only after perform-
ing a resection that included a systematic abdominal and tho-
racic lymphadenectomy. Our results indicate that patients
with transmural tumors and more than 4 involved lymph
nodes are at especially high risk for recurrence and are
unlikely to be cured with surgery alone. We have incorporat-
ed these results into our treatment protocol and believe that
this group of patients should be targeted for neoadjuvant and
adjuvant therapy.
Dr Little. I would like to make one complimentary com-
ment in closing. This paper based survival statistics on all
deaths, perioperative deaths as well as the late deaths due to
cancer, and that is the way these data should be presented. It
is the most honest way, and I hope that others will adopt this
method as well.
Dr Douglas E. Wood (Seattle, Wash). I had some of the
same comments and questions that Dr Little had. The recur-
rence rate and survival of patients after esophagectomy for
esophageal cancer is related to the biology of the tumor. One
of your early slides showed that the majority of your survivors
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had N0 disease. If those patients are the long-term survivors,
it is hard to imagine that an extended procedure is going to
benefit them. In fact, there is no good evidence in any series
that a more radical resection does result in better survival. I
would urge us all to participate in developing prospective tri-
als to examine the role of neoadjuvant and adjuvant thera-
pies and different surgical techniques rather than multiple
parochial case studies within each of our institutions.
You had mentioned in the conclusion a potential role for
adjuvant therapy. No data have been presented that show that
postoperative or adjuvant therapy improves survival in
esophageal cancer. Can you tell me what you mean by select-
ing patients for adjuvant therapy?
Dr Nigro. We believe that patients with N0 disease will not
benefit from neoadjuvant or systemic therapy. We now know
that those patients with greater than 4 involved nodes have an
extremely poor prognosis, and we believe that it would be
more appropriate to target this group for systemic therapy in
a manner analogous to the application of adjuvant therapy in
colon adenocarcinoma.
Dr Wood. If you could identify that before resection,
would you prefer to avoid resection in those patients and treat
them nonoperatively? I would point out that not only did
patients with more than 4 positive lymph nodes do poorly, but
the patients with any lymph node metastases as a group did
not do well in your study.
Dr Nigro. The presence of lymph node metastases is a poor
prognostic indicator, but it remains difficult to determine this
preoperatively. Although patients with involved nodes have a
poor prognosis, local disease control remains an important
goal that is rarely obtained with nonoperative therapy. In our
opinion, surgical resection provides the best palliation for
patients with advanced tumors and is the only therapy that is
potentially curative.
Dr Wood. Have you used endoscopic ultrasound, computed
tomographic scanning, or any of the laparoscopic methods of
sampling lymph nodes before resection?
Dr Nigro. Currently our preoperative assessment includes
a computed tomographic scan of the abdomen and pelvis and
endoscopic ultrasound. As we all know, endoscopic ultra-
sound is able to determine depth of tumor invasion in approx-
imately 80% of cases, but it does not always accurately reveal
node status. We do not believe it is beneficial to add addi-
tional invasive procedures such as thoracoscopy and
laparoscopy to stage the disease when we can obtain accurate
disease staging, along with local disease control and good
survival, with one primary operation.
Dr John R. Benfield (Sacramento, Calif). I think there is
no better place than The Western Thoracic Surgical Associ-
ation to recognize that thoracic surgery is a family affair. Dr
John Nigro is the son of one of my close friends who is also
a thoracic surgeon.
Dr Nigro, I think you said that one of your patients who
had a peritracheal recurrence had a second resection and then
became a long-term survivor. Did I hear that correctly?
Dr Nigro. That is correct.
Dr Benfield. Is it your practice to reoperate on patients
who have recurrence? Did this patient have additional non-
operative therapy? If so, do you think the resections or the
nonoperative treatment was more important in achieving
long-term survival after reresection?
Dr Nigro. We are in the process of reviewing our experi-
ence with these patients. We now have a series of 5 to 7
patients with isolated lymph node recurrence who have
undergone a second resection and now have no evidence of
disease. We believe that these patients can benefit from
surgery. The patient you referred to received no therapy other
than surgery.
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